ST Pharm Co Ltd

The company's capital structure is characterized by a low debt-to-equity ratio of 0.13, indicating a conservative leverage profile. Its liquidity position is mixed, with a current ratio of 2.26, but cash and equivalents are reported at -320 KRW, suggesting a net cash outflow. This negative cash position, combined with total liabilities of 189.1 billion KRW, raises concerns about short-term liquidity. Profitability metrics show a return on equity (ROE) of 9.27% and a return on assets (ROA) of 7.03%, both of which are strong relative to the industry median. The company's gross margin is 41.06% (136.2 billion KRW gross profit on 331.7 billion KRW revenue), and its operating margin is 16.57% (54.97 billion KRW operating income on 331.7 billion KRW revenue), indicating efficient cost management and pricing power. Geographically, the company's revenue is concentrated in South Korea, with no disclosed international operations. Segment-wise, the company operates as a single business unit, with no material diversification across therapeutic areas or product lines. This concentration increases exposure to domestic regulatory and economic risks. Looking ahead, the company is projected to grow revenue by 12.3% in the current fiscal year and 8.1% in the next, driven by new product launches and market expansion. However, capital expenditures are negative at -47.29 billion KRW, suggesting asset divestitures or write-downs rather than growth investments. Risk factors include a medium liquidity risk due to the negative cash position and a low dilution risk, with no significant share issuance expected in the near term. The company has not disclosed any material regulatory or geopolitical risks, but its reliance on the South Korean market makes it vulnerable to domestic policy shifts. Recent events include a 10-K filing that disclosed no material changes in business operations or financial condition. Analysts have issued a mean price target of 196,090.91 KRW, with a median of 200,000 KRW, and a mean recommendation of 1.50 (strong buy to hold), indicating a generally positive outlook.